The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of dacarbazine for metastatic colorectal cancer with determined MGMT status.
Alessio Amatu
No relevant relationships to disclose
Andrea Sartore-Bianchi
Honoraria - Amgen; Merck Serono
Katia Bencardino
No relevant relationships to disclose
Catia Moutinho
No relevant relationships to disclose
Giovanna Marrapese
No relevant relationships to disclose
Alessandro Belotti
No relevant relationships to disclose
Alessandra Gambaro
No relevant relationships to disclose
Andrea Cassingena
No relevant relationships to disclose
Filippo Venturini
No relevant relationships to disclose
Felicia Giacobbe
No relevant relationships to disclose
Andrea Sporchia
No relevant relationships to disclose
Calogero Lauricella
No relevant relationships to disclose
Roberta Schiavo
No relevant relationships to disclose
Manel Esteller
No relevant relationships to disclose
Salvatore Siena
Consultant or Advisory Role - Amgen; Celgene